2021
Potential Implications of a Type 1 Interferon Gene Signature on COVID-19 Severity and Chronic Inflammation in Sickle Cell Disease
Madany E, Okwan-Duodu D, Balbuena-Merle R, Hendrickson JE, Gibb DR. Potential Implications of a Type 1 Interferon Gene Signature on COVID-19 Severity and Chronic Inflammation in Sickle Cell Disease. Frontiers In Medicine 2021, 8: 679030. PMID: 34368185, PMCID: PMC8339405, DOI: 10.3389/fmed.2021.679030.Peer-Reviewed Original ResearchSickle cell diseaseCOVID-19 severityIFNα/βType 1 interferonCell diseaseSARS-CoV-2 infectionType 1 interferon responseCorona Virus Disease-19 (COVID-19) pandemicCohort of patientsMajority of patientsInterferon gene signatureIFNα/β productionRace-matched controlsDisease-19 pandemicCOVID-19Express elevated levelsMajority of evidenceSCD diseaseSevere sequelaeChronic inflammationFavorable outcomeVariable progressionClinical consequencesGeneral populationPatients
2018
Bullous hemorrhagic dermatosis is an under-recognized side effect of full dose low-molecular weight heparin: a case report and review of the literature
Russo A, Curtis S, Balbuena-Merle R, Wadia R, Wong E, Chao HH. Bullous hemorrhagic dermatosis is an under-recognized side effect of full dose low-molecular weight heparin: a case report and review of the literature. Experimental Hematology & Oncology 2018, 7: 15. PMID: 29989046, PMCID: PMC6035443, DOI: 10.1186/s40164-018-0108-7.BooksLow molecular weight heparinBullous hemorrhagic dermatosisWeight heparinCoagulation testingFull-dose low molecular weight heparinMajority of patientsSmall case seriesMolecular weight heparinDays of administrationSearch of PubMedSite of injectionCase seriesIntracranial hemorrhageOvid EmbaseCase reportElderly menLate diagnosisTherapeutic rangeOvid MEDLINEAnticoagulationSide effectsPatientsTherapeutic interventionsNew casesDifferent anticoagulants